Literature DB >> 25143390

Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms.

Hiroki Ishii1, Masao Saitoh2, Kei Sakamoto3, Tetsuo Kondo4, Ryohei Katoh4, Shota Tanaka5, Mitsuyoshi Motizuki2, Keisuke Masuyama5, Keiji Miyazawa6.   

Abstract

ESRP1 (epithelial splicing regulatory protein 1) and ESRP2 regulate alternative splicing events associated with epithelial phenotypes of cells, and both are down-regulated during the epithelial-mesenchymal transition. However, little is known about their expression and functions during carcinogenesis. In this study, we found that expression of both ESRP1 and ESRP2 is plastic: during oral squamous cell carcinogenesis, these proteins are up-regulated relative to their levels in normal epithelium but down-regulated in invasive fronts. Importantly, ESRP1 and ESRP2 are re-expressed in the lymph nodes, where carcinoma cells metastasize and colonize. In head and neck carcinoma cell lines, ESRP1 and ESRP2 suppress cancer cell motility through distinct mechanisms: knockdown of ESRP1 affects the dynamics of the actin cytoskeleton through induction of Rac1b, whereas knockdown of ESRP2 attenuates cell-cell adhesion through increased expression of epithelial-mesenchymal transition-associated transcription factors. Down-regulation of ESRP1 and ESRP2 is thus closely associated with a motile phenotype of cancer cells.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Cancer Biology; Cell Invasion; Cell Motility; ESRP; Epithelial-Mesenchymal Transition (EMT); RNA Splicing; Rac1b; SIP1; δEF1

Mesh:

Substances:

Year:  2014        PMID: 25143390      PMCID: PMC4183779          DOI: 10.1074/jbc.M114.589432

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Regulation of vimentin by SIP1 in human epithelial breast tumor cells.

Authors:  S Bindels; M Mestdagt; C Vandewalle; N Jacobs; L Volders; A Noël; F van Roy; G Berx; J-M Foidart; C Gilles
Journal:  Oncogene       Date:  2006-03-27       Impact factor: 9.867

2.  RNA-binding motif protein 35A is a novel tumor suppressor for colorectal cancer.

Authors:  Olga V Leontieva; Yuri Ionov
Journal:  Cell Cycle       Date:  2009-02-22       Impact factor: 4.534

3.  Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways.

Authors:  Vânia Gonçalves; Paulo Matos; Peter Jordan
Journal:  Hum Mol Genet       Date:  2009-07-13       Impact factor: 6.150

4.  A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition.

Authors:  Cameron P Bracken; Philip A Gregory; Natasha Kolesnikoff; Andrew G Bert; Jun Wang; M Frances Shannon; Gregory J Goodall
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

5.  ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing.

Authors:  Claude C Warzecha; Trey K Sato; Behnam Nabet; John B Hogenesch; Russ P Carstens
Journal:  Mol Cell       Date:  2009-03-13       Impact factor: 17.970

Review 6.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.

Authors:  Kornelia Polyak; Robert A Weinberg
Journal:  Nat Rev Cancer       Date:  2009-03-05       Impact factor: 60.716

7.  CD4+ T helper responses in squamous cell carcinoma of the head and neck.

Authors:  Kazuaki Chikamatsu; Koichi Sakakura; Takanori Yamamoto; Nobuhiko Furuya; Theresa L Whiteside; Keisuke Masuyama
Journal:  Oral Oncol       Date:  2008-01-24       Impact factor: 5.337

8.  Erk5 controls Slug expression and keratinocyte activation during wound healing.

Authors:  Valerie Arnoux; Mayssaa Nassour; Annie L'Helgoualc'h; Robert A Hipskind; Pierre Savagner
Journal:  Mol Biol Cell       Date:  2008-08-20       Impact factor: 4.138

9.  SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions.

Authors:  Cindy Vandewalle; Joke Comijn; Bram De Craene; Petra Vermassen; Erik Bruyneel; Henriette Andersen; Eugene Tulchinsky; Frans Van Roy; Geert Berx
Journal:  Nucleic Acids Res       Date:  2005-11-24       Impact factor: 16.971

10.  An Id-like molecule, HHM, is a synexpression group-restricted regulator of TGF-beta signalling.

Authors:  Hiroaki Ikushima; Akiyoshi Komuro; Kazunobu Isogaya; Masahiko Shinozaki; Ulf Hellman; Keiji Miyazawa; Kohei Miyazono
Journal:  EMBO J       Date:  2008-10-16       Impact factor: 11.598

View more
  68 in total

1.  Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Authors:  Clarissa Gerhauser; Francesco Favero; Thomas Risch; Ronald Simon; Lars Feuerbach; Yassen Assenov; Doreen Heckmann; Nikos Sidiropoulos; Sebastian M Waszak; Daniel Hübschmann; Alfonso Urbanucci; Etsehiwot G Girma; Vladimir Kuryshev; Leszek J Klimczak; Natalie Saini; Adrian M Stütz; Dieter Weichenhan; Lisa-Marie Böttcher; Reka Toth; Josephine D Hendriksen; Christina Koop; Pavlo Lutsik; Sören Matzk; Hans-Jörg Warnatz; Vyacheslav Amstislavskiy; Clarissa Feuerstein; Benjamin Raeder; Olga Bogatyrova; Eva-Maria Schmitz; Claudia Hube-Magg; Martina Kluth; Hartwig Huland; Markus Graefen; Chris Lawerenz; Gervaise H Henry; Takafumi N Yamaguchi; Alicia Malewska; Jan Meiners; Daniela Schilling; Eva Reisinger; Roland Eils; Matthias Schlesner; Douglas W Strand; Robert G Bristow; Paul C Boutros; Christof von Kalle; Dmitry Gordenin; Holger Sültmann; Benedikt Brors; Guido Sauter; Christoph Plass; Marie-Laure Yaspo; Jan O Korbel; Thorsten Schlomm; Joachim Weischenfeldt
Journal:  Cancer Cell       Date:  2018-12-10       Impact factor: 31.743

Review 2.  Alternative splicing and cancer metastasis: prognostic and therapeutic applications.

Authors:  Diego M Marzese; Ayla O Manughian-Peter; Javier I J Orozco; Dave S B Hoon
Journal:  Clin Exp Metastasis       Date:  2018-05-29       Impact factor: 5.150

Review 3.  Connecting the dots: chromatin and alternative splicing in EMT.

Authors:  Jessica A Warns; James R Davie; Archana Dhasarathy
Journal:  Biochem Cell Biol       Date:  2015-07-07       Impact factor: 3.626

4.  TGF-β1 promotes epithelial-to-mesenchymal transition and stemness of prostate cancer cells by inducing PCBP1 degradation and alternative splicing of CD44.

Authors:  Qi Chen; Meng Gu; Zhi-Kang Cai; Hu Zhao; Shi-Cheng Sun; Chong Liu; Ming Zhan; Yan-Bo Chen; Zhong Wang
Journal:  Cell Mol Life Sci       Date:  2020-05-21       Impact factor: 9.261

5.  Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells.

Authors:  Tonya C Walser; Zhe Jing; Linh M Tran; Ying Q Lin; Natalie Yakobian; Gerald Wang; Kostyantyn Krysan; Li X Zhu; Sherven Sharma; Mi-Heon Lee; John A Belperio; Aik T Ooi; Brigitte N Gomperts; Jerry W Shay; Jill E Larsen; John D Minna; Long-Sheng Hong; Michael C Fishbein; Steven M Dubinett
Journal:  Cancer Res       Date:  2018-02-05       Impact factor: 12.701

6.  Proteogenomic Characterization of Endometrial Carcinoma.

Authors:  Yongchao Dou; Emily A Kawaler; Daniel Cui Zhou; Marina A Gritsenko; Chen Huang; Lili Blumenberg; Alla Karpova; Vladislav A Petyuk; Sara R Savage; Shankha Satpathy; Wenke Liu; Yige Wu; Chia-Feng Tsai; Bo Wen; Zhi Li; Song Cao; Jamie Moon; Zhiao Shi; MacIntosh Cornwell; Matthew A Wyczalkowski; Rosalie K Chu; Suhas Vasaikar; Hua Zhou; Qingsong Gao; Ronald J Moore; Kai Li; Sunantha Sethuraman; Matthew E Monroe; Rui Zhao; David Heiman; Karsten Krug; Karl Clauser; Ramani Kothadia; Yosef Maruvka; Alexander R Pico; Amanda E Oliphant; Emily L Hoskins; Samuel L Pugh; Sean J I Beecroft; David W Adams; Jonathan C Jarman; Andy Kong; Hui-Yin Chang; Boris Reva; Yuxing Liao; Dmitry Rykunov; Antonio Colaprico; Xi Steven Chen; Andrzej Czekański; Marcin Jędryka; Rafał Matkowski; Maciej Wiznerowicz; Tara Hiltke; Emily Boja; Christopher R Kinsinger; Mehdi Mesri; Ana I Robles; Henry Rodriguez; David Mutch; Katherine Fuh; Matthew J Ellis; Deborah DeLair; Mathangi Thiagarajan; D R Mani; Gad Getz; Michael Noble; Alexey I Nesvizhskii; Pei Wang; Matthew L Anderson; Douglas A Levine; Richard D Smith; Samuel H Payne; Kelly V Ruggles; Karin D Rodland; Li Ding; Bing Zhang; Tao Liu; David Fenyö
Journal:  Cell       Date:  2020-02-13       Impact factor: 41.582

Review 7.  Luteolin and cancer metastasis suppression: focus on the role of epithelial to mesenchymal transition.

Authors:  Yaseen Hussain; Jing Hao Cui; Haroon Khan; Michael Aschner; Gaber El-Saber Batiha; Philippe Jeandet
Journal:  Med Oncol       Date:  2021-05-05       Impact factor: 3.064

8.  IDH1 mutation-associated long non-coding RNA expression profile changes in glioma.

Authors:  Xiao-Qin Zhang; Karrie Mei-Yee Kiang; Yue-Chun Wang; Jenny Kan-Suen Pu; Amy Ho; Stephen Yin Cheng; Derek Lee; Ping-De Zhang; Jia-Jing Chen; Wai-Man Lui; Ching-Fai Fung; Gilberto Ka-Kit Leung
Journal:  J Neurooncol       Date:  2015-09-03       Impact factor: 4.130

Review 9.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

10.  Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells.

Authors:  Karina E Gomez; FangLong Wu; Stephen B Keysar; J Jason Morton; Bettina Miller; Tugs-Saikhan Chimed; Phuong N Le; Cera Nieto; Farshad N Chowdhury; Anit Tyagi; Traci R Lyons; Christian D Young; Hongmei Zhou; Hilary L Somerset; Xiao-Jing Wang; Antonio Jimeno
Journal:  Cancer Res       Date:  2020-08-14       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.